-
Y.
Nikiforov
(2004)
Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas
Endocrine Pathology, 15
-
K.
Spurgers,
D.
Gold,
K.
Coombes,
Nicole
Bohnenstiehl,
B.
Mullins,
R.
Meyn,
C.
Logothetis,
T.
McDonnell
(2006)
Identification of Cell Cycle Regulatory Genes as Principal Targets of p53-mediated Transcriptional Repression*
Journal of Biological Chemistry, 281
-
Silvia
Agostino,
S.
Strano,
Velia
Emiliozzi,
V.
Zerbini,
M.
Mottolese,
A.
Sacchi,
G.
Blandino,
G.
Piaggio
(2006)
Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation.
Cancer cell, 10 3
-
(2007)
Cancer Research Cancer Res
-
T.
Uchiumi,
D.
Longo,
D.
Ferris
(1997)
Cell Cycle Regulation of the Human Polo-like Kinase (PLK) Promoter*
The Journal of Biological Chemistry, 272
-
M.
Olivier,
R.
Eeles,
M.
Hollstein,
Mohammed
Khan,
C.
Harris,
P.
Hainaut
(2002)
The IARC TP53 database: New online mutation analysis and recommendations to users
Human Mutation, 19
-
Wencheng
Zhu,
P.
Giangrande,
J.
Nevins
(2004)
E2Fs link the control of G1/S and G2/M transcription
The EMBO Journal, 23
-
P.
Pallante,
M.
Berlingieri,
G.
Troncone,
M.
Kruhøffer,
T.
Ørntoft,
G.
Viglietto,
A.
Caleo,
I.
Migliaccio,
M.
Decaussin-Petrucci,
M.
Santoro,
L.
Palombini,
A.
Fusco
(2005)
UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas
British Journal of Cancer, 93
-
L.
Fiore,
Luca
Pollina,
Gabriella
Fontanini,
Rosario
Casalone,
M.
Berlingieri,
R.
Giannini,
Furio
Pacini,
Paolo
Miccoli,
Antonio
Toniolo,
Alfredo
Fusco,
Fulvio
Basolo
(1997)
Cytokine production by a new undifferentiated human thyroid carcinoma cell line, FB-1.
The Journal of clinical endocrinology and metabolism, 82 12
-
J.
Fagin,
K.
Matsuo,
A.
Karmakar,
Dan-Lin
Chen,
Shi
Tang,
H.
Koeffler
(1993)
High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
The Journal of clinical investigation, 91 1
-
Guojun
Wu,
E.
Mambo,
Zhongmin
Guo,
Shuiying
Hu,
Xin
Huang,
S.
Gollin,
B.
Trink,
P.
Ladenson,
D.
Sidransky,
Mingzhao
Xing
(2005)
Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors.
The Journal of clinical endocrinology and metabolism, 90 8
-
T.
Kondo,
S.
Ezzat,
S.
Asa
(2006)
Pathogenetic mechanisms in thyroid follicular-cell neoplasia
Nature Reviews Cancer, 6
-
G.
García-Rostán,
Â.
Costa,
Isabel
Pereira-Castro,
G.
Salvatore,
R.
Hernández,
Mario
Hermsem,
A.
Herrero,
A.
Fusco,
J.
Cameselle-Teijeiro,
M.
Santoro
(2005)
Mutation of the PIK3CA gene in anaplastic thyroid cancer.
Cancer research, 65 22
-
Francesco
Curcio,
F.
Ambesi-Impiombato,
G.
Perrella,
H.
Coon
(1994)
Long-term culture and functional characterization of follicular cells from adult normal human thyroids.
Proceedings of the National Academy of Sciences of the United States of America, 91 19
-
R.
Malaguarnera,
V.
Vella,
R.
Vigneri,
F.
Frasca
(2007)
p53 family proteins in thyroid cancer.
Endocrine-related cancer, 14 1
-
P.
Kho,
Zhen
Wang,
Zhuang
Li,
Yuqing
Li,
Joon-Lin
Chew,
H.
Ng,
E.
Liu,
Qiang
Yu
(2004)
p53-regulated Transcriptional Program Associated with Genotoxic Stress-induced Apoptosis*
Journal of Biological Chemistry, 279
-
S.
Carter,
A.
Eklund,
I.
Kohane,
L.
Harris,
Z.
Szallasi
(2006)
A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers
Nature Genetics, 38
-
J.
Fagin
(2004)
How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy.
The Journal of endocrinology, 183 2
-
V.
Wreesmann,
R.
Ghossein,
S.
Patel,
C.
Harris,
E.
Schnaser,
A.
Shaha,
R.
Tuttle,
Jatin
Shah,
P.
Rao,
Bhuvanesh
Singh
(2002)
Genome-wide appraisal of thyroid cancer progression.
The American journal of pathology, 161 5
-
T.
Guida,
G.
Salvatore,
P.
Faviana,
R.
Giannini,
G.
García-Rostán,
L.
Provitera,
F.
Basolo,
A.
Fusco,
F.
Carlomagno,
M.
Santoro
(2005)
Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma.
The Journal of clinical endocrinology and metabolism, 90 8
-
M.
Bittner,
P.
Meltzer,
Yidong
Chen,
Yong-hui
Jiang,
E.
Seftor,
M.
Hendrix,
M.
Radmacher,
R.
Simon,
Z.
Yakhini,
A.
Ben-Dor,
N.
Sampas,
E.
Dougherty,
E.
Wang,
F.
Marincola,
C.
Gooden,
J.
Lueders,
A.
Glatfelter,
Pamela
Pollock,
J.
Carpten,
E.
Gillanders,
D.
Leja,
K.
Dietrich,
C.
Beaudry,
M.
Berens,
D.
Alberts,
V.
Sondak
(2000)
Molecular classification of cutaneous malignant melanoma by gene expression profiling
Nature, 406
-
Kiranmai
Gumireddy,
M.
Reddy,
S.
Cosenza,
R.
Nathan,
S.
Baker,
Nabisa
Papathi,
Jian-Dong
Jiang,
J.
Holland,
Elala
Reddy
(2005)
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.
Cancer cell, 7 3
-
Xiaoqi
Liu,
M.
Lei,
R.
Erikson
(2006)
Normal Cells, but Not Cancer Cells, Survive Severe Plk1 Depletion
Molecular and Cellular Biology, 26
-
J.
Nevins
(2001)
The Rb/E2F pathway and cancer.
Human molecular genetics, 10 7
-
N.
Heldin,
D.
Cvejić,
S.
Smeds,
B.
Westermark
(1991)
Coexpression of functionally active receptors for thyrotropin and platelet-derived growth factor in human thyroid carcinoma cells.
Endocrinology, 129 4
-
J.
Gioanni,
E.
Zanghellini,
C.
Mazeau,
D.
Zhang,
A.
Courdi,
M.
Farges,
J.
Lambert,
H.
Duplay,
M.
Schneider
(1991)
[Characterization of a human cell line from an anaplastic carcinoma of the thyroid gland].
Bulletin du cancer, 78 11
-
G.
Pierantoni,
C.
Rinaldo,
M.
Mottolese,
A.
Benedetto,
F.
Esposito,
S.
Soddu,
A.
Fusco
(2007)
High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2.
The Journal of clinical investigation, 117 3
-
Y.
Tabach,
M.
Milyavsky,
I.
Shats,
R.
Brosh,
O.
Zuk,
Assif
Yitzhaky,
Roberto
Mantovani,
E.
Domany,
Varda
Rotter,
Y.
Pilpel
(2005)
The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation
Molecular Systems Biology, 1
-
Chaim
Linhart,
R.
Elkon,
Y.
Shiloh,
R.
Shamir
(2005)
Deciphering Transcriptional Regulatory Elements That Encode Specific Cell-Cycle Phasing by Comparative Genomics Analysis
Cell Cycle, 4
-
A.
Espinosa,
L.
Porchia,
M.
Ringel
(2006)
Targeting BRAF in thyroid cancer
British Journal of Cancer, 96
-
Yuan
Jiang,
J.
Lueders,
A.
Glatfelter,
C.
Gooden,
Mike
Bittner
(2001)
Profiling Human Gene Expression with cDNA Microarrays
Current Protocols in Molecular Biology, 53
-
M.
Whitfield,
Lacy
George,
Gavin
Grant,
C.
Perou
(2006)
Common markers of proliferation
Nature Reviews Cancer, 6
-
M.
Bhonde,
M.
Hanski,
J.
Budczies,
Minhton
Cao,
B.
Gillissen,
Dhatchana
Moorthy,
F.
Simonetta,
H.
Scherübl,
Matthias
Truss,
C.
Hagemeier,
H.
Mewes,
P.
Daniel,
M.
Zeitz,
C.
Hanski
(2006)
DNA Damage-induced Expression of p53 Suppresses Mitotic Checkpoint Kinase hMps1
Journal of Biological Chemistry, 281
-
M.
HEDINGER,
Marc
Williams,
MD
SOBIN,
MD
Caillou,
Villejuif
Gustave-Roussy,
B.
Egloff,
Oleg
Khmelnitsky,
MD
Vickery,
E.
Williams
(1989)
The WHO histological classification of thyroid tumors: A commentary on the second edition
Cancer, 63
-
J.
Gioanni,
E.
Zanghellini,
C.
Mazeau,
D.
Zhang,
A.
Courdi,
Farges
Mf,
J.
Lambert,
H.
Duplay,
Maurice
Schneider
(1991)
Caractérisation d'une lignée cellulaire humaine provenant d'un carcinome anaplasique de la thyroïde.
Bulletin Du Cancer, 78
-
K.
Strebhardt,
A.
Ullrich
(2006)
Targeting polo-like kinase 1 for cancer therapy
Nature Reviews Cancer, 6
-
K.
Ain,
S.
Tofiq,
K.
Taylor
(1996)
Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo.
The Journal of clinical endocrinology and metabolism, 81 10
-
Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Effects of p53-Expressing Adenovirus on the Chemosensitivity and Differentiation of Anaplastic
-
Bing
Ren,
Hieu
Cam,
Yasuhiko
Takahashi,
T.
Volkert,
Jolyon
Terragni,
R.
Young,
B.
Dynlacht
(2002)
E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints.
Genes & development, 16 2